A Phase I and Randomized Placebo-Controlled Phase II Trial of Bevacizumab plus Dasatinib in Patients with Recurrent Glioblastoma (GBM): Alliance/NCCTG N0872
- Citation:
- Cancer vol 125 (21) 3790-3800
- Year:
- 2019
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 9
- Parents:
- 2274
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Neuro-Onc
- Sec. Committees:
- Health Outcomes
- Pharmas:
- Grants:
- UG1CA189823, U10CA180821, U10CA180882, U10CA180833
- Corr. Author:
- Authors:
- Evanthia Galanis S. Keith Anderson Erin L. Twohy Xiomara W. Carrero Jesse G. Dixon David Dinh Tran Suriya A. Jeyapalan Daniel M. Anderson Timothy J. Kaufmann Ryan W. Feathers Caterina Giannini Jan C. Buckner Panos Z. Anastasiadis David Schiff
- Networks:
- LAPS-MN026, LAPS-MO011, METROMIN, RI005, VA009
- Study
- NCCTG-N0872
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- bevacizumab, dasatinib, Src family kinase inhibitors, recurrent glioblastoma, phase II trial